Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Operating Leases: 2017-2025

Historic Operating Leases for AC Immune (ACIU) over the last 7 years, with Sep 2025 value amounting to $4.5 million.

  • AC Immune's Operating Leases rose 63.93% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 63.93%. This contributed to the annual value of $4.5 million for FY2025, which is N/A change from last year.
  • Per AC Immune's latest filing, its Operating Leases stood at $4.5 million for Q3 2025, which was up 96,350.62% from $4,687 recorded in Q2 2025.
  • AC Immune's Operating Leases' 5-year high stood at $2.3 billion during Q2 2021, with a 5-year trough of $4,687 in Q2 2025.
  • Its 3-year average for Operating Leases is $2.5 million, with a median of $2.8 million in 2024.
  • In the last 5 years, AC Immune's Operating Leases surged by 140,132.59% in 2021 and then tumbled by 99.91% in 2022.
  • Over the past 5 years, AC Immune's Operating Leases (Quarterly) stood at $2.5 million in 2021, then fell by 7.84% to $2.3 million in 2022, then soared by 36.18% to $3.2 million in 2023, then tumbled by 99.84% to $5,024 in 2024, then soared by 63.93% to $4.5 million in 2025.
  • Its last three reported values are $4.5 million in Q3 2025, $4,687 for Q2 2025, and $4.6 million during Q1 2025.